MedTrace Logo

Allogeneic Mesenchymal Stem Cells for the Survivors of Ischemic Stroke Trial (ASSIST)

NCT04590118 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-03-31

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety, tolerability, and preliminary efficacy of single injection of it-hMSC in patients with ischemic stroke in a multicenter, blind, randomized, placebo controlled trial

Conditions

Interventions

DRUG

it-hMSC

Single intravenous infusion of it-hMSC for ischemic stroke patients

DRUG

Placebo

Single intravenous infusion of 1 ml/kg placebo

Sponsors & Collaborators

  • Beijing Tiantan Hospital

    collaborator OTHER

  • Jiuzhitang Maker (Beijing) Cell Technology Co.,Ltd.

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-04-26
Primary Completion
2023-04-01
Completion
2023-08-01

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04590118 on ClinicalTrials.gov